These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 9535308)

  • 21. [Myasthenia gravis (1). Experimental myasthenia gravis--a tool for the study of the pathogenesis, diagnosis and treatment of myasthenia gravis].
    Heilbronn E
    Lakartidningen; 1978 Oct; 75(41):3663-4, 3669. PubMed ID: 692231
    [No Abstract]   [Full Text] [Related]  

  • 22. Neuromuscular disease: acute treatment for myasthenia gravis.
    Gilhus NE
    Nat Rev Neurol; 2011 Mar; 7(3):132-4. PubMed ID: 21386868
    [No Abstract]   [Full Text] [Related]  

  • 23. Prior damage to lower motor neuron triggering myasthenia gravis.
    Steiner I; Goldstein L; Hellmann MA; Lotan I
    Muscle Nerve; 2016 Jun; 54(1):167-9. PubMed ID: 26789735
    [No Abstract]   [Full Text] [Related]  

  • 24. [Myasthenia gravis in newborn infants--pathological mechanism, clinical symptomatology and therapeutic procedures].
    Krauze M; Musialik E; Swietliński J; Litwa K; Latko E; Górny J; Sobczyk J
    Wiad Lek; 1992 Aug; 45(15-16):610-4. PubMed ID: 1488831
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasma treatment in diseases of the neuromuscular junction.
    Cornelio F; Antozzi C; Confalonieri P; Baggi F; Mantegazza R
    Ann N Y Acad Sci; 1998 May; 841():803-10. PubMed ID: 9668333
    [No Abstract]   [Full Text] [Related]  

  • 26. Neonatal myasthenia gravis in the infant of an asymptomatic thymectomized mother.
    Olanow CW; Lane RJ; Hull KL; Roses AD
    Can J Neurol Sci; 1982 May; 9(2):85-7. PubMed ID: 7104893
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [A case of myasthenia gravis with anti-MuSK antibodies showing a dramatic improvement with plasma exchange].
    Suzuki H; Motomura M; Yoshimura T; Shiraishi H; Mitsui Y; Hasegawa T; Atsumi M; Kitaguchi M; Kusunoki S
    Rinsho Shinkeigaku; 2005 Jul; 45(7):510-3. PubMed ID: 16119834
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Myasthenia gravis: new therapeutic approaches based on pathophysiology.
    Lewis RA
    J Neurol Sci; 2013 Oct; 333(1-2):93-8. PubMed ID: 23938353
    [TBL] [Abstract][Full Text] [Related]  

  • 29. IVIG Versus PLEX in the Treatment of Worsening Myasthenia Gravis: What is the Evidence?: A Critically Appraised Topic.
    Dhawan PS; Goodman BP; Harper CM; Bosch PE; Hoffman-Snyder CR; Wellik KE; Wingerchuk DM; Demaerschalk BM
    Neurologist; 2015 May; 19(5):145-8. PubMed ID: 25970838
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group.
    Gajdos P; Chevret S; Clair B; Tranchant C; Chastang C
    Ann Neurol; 1997 Jun; 41(6):789-96. PubMed ID: 9189040
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Myasthenic crisis. Response to plasmapheresis following failure of intravenous gamma-globulin.
    Stricker RB; Kwiatkowska BJ; Habis JA; Kiprov DD
    Arch Neurol; 1993 Aug; 50(8):837-40. PubMed ID: 8352670
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice.
    Klooster R; Plomp JJ; Huijbers MG; Niks EH; Straasheijm KR; Detmers FJ; Hermans PW; Sleijpen K; Verrips A; Losen M; Martinez-Martinez P; De Baets MH; van der Maarel SM; Verschuuren JJ
    Brain; 2012 Apr; 135(Pt 4):1081-101. PubMed ID: 22396395
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Antibodies to acetylcholine receptor. Diagnosis and therapeutic interest in myasthenia gravis (author's transl)].
    de Crousaz G
    Ann Chir; 1980 Mar; 34(3):188-92. PubMed ID: 7369693
    [No Abstract]   [Full Text] [Related]  

  • 34. Plasma exchange in myasthenia gravis: effect on anti-AChR antibodies and other autoantibodies.
    Thorlacius S; Lefvert AK; Aarli JA; Gilhus NE; Halvorsen K; Hofstad H; Matre R; Tönder O
    Acta Neurol Scand; 1986 Dec; 74(6):486-90. PubMed ID: 3825504
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Memory B cell resurgence requires repeated rituximab in myasthenia gravis.
    Muto K; Matsui N; Unai Y; Sakai W; Haji S; Udaka K; Miki H; Furukawa T; Abe M; Kaji R
    Neuromuscul Disord; 2017 Oct; 27(10):918-922. PubMed ID: 28694074
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Maintenance IVIg therapy in myasthenia gravis does not affect disease activity.
    Hellmann MA; Mosberg-Galili R; Lotan I; Steiner I
    J Neurol Sci; 2014 Mar; 338(1-2):39-42. PubMed ID: 24267740
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Allogeneic hematopoietic cell transplantation for refractory myasthenia gravis.
    Strober J; Cowan MJ; Horn BN
    Arch Neurol; 2009 May; 66(5):659-61. PubMed ID: 19433668
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Autoimmune myasthenia gravis.
    Lopate G; Pestronk A
    Hosp Pract (Off Ed); 1993 Jan; 28(1):109-12, 115-7, 121-2, passim. PubMed ID: 8380423
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparison of the effectiveness of intravenous immunoglobulin and plasma exchange as preoperative therapy of myasthenia gravis.
    Jensen P; Bril V
    J Clin Neuromuscul Dis; 2008 Mar; 9(3):352-5. PubMed ID: 18344718
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts.
    Guptill JT; Sanders DB; Evoli A
    Muscle Nerve; 2011 Jul; 44(1):36-40. PubMed ID: 21674519
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.